Impact of Corporate Restructuring on Malaysian Banks' Problem Loans Still Muted Mar 02

  • ID: 2030066
  • March 2002
  • Region: Malaysia
  • Standard & Poors
1 of 3

SINGAPORE (Standard & Poor's) March 4, 2002--Standard & Poor's today said that one key element leading to the revision of the outlook on the sovereign ratings on Malaysia to positive from stable--corporate restructuring, which has reduced the drag of nonproductive companies on the economy--remains muted in respect of Malaysia's banking sector's problem loans. The banking industry's nonperforming loans (NPL), defined as those past due by 90 days, have remained at about 18% of gross loans throughout the fourth quarter of 2001. Although some leading banks, such as Malayan Banking Berhad (BBB-/Stable/A-3), are reporting improved recoveries on NPLs, others are seeing their NPL ratios edge up. Standard & Poor's will reassess its ratings and outlooks on Malaysian banks once it is...

Companies mentioned in this report are:
- Malayan Banking Bhd.

Action: S&P Event

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Malayan Banking Bhd.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.